| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTSE |
| Uniprot No | P14091-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-396aa |
| 氨基酸序列 | SLHRVPLRRHPSLKKKLRARSQLSEFWKSHNLDMIQFTESCSMDQSAKEP LINYLDMEYFGTISIGSPPQNFTVIFDTGSSNLWVPSVYCTSPACKTHSR FQPSQSSTYSQPGQSFSIQYGTGSLSGIIGADQVSVEGLTVVGQQFGESV TEPGQTFVDAEFDGILGLGYPSLAVGGVTPVFDNMMAQNLVDLPMFSVYM SSNPEGGAGSELIFGGYDHSHFSGSLNWVPVTKQAYWQIALDNIQVGGTV MFCSEGCQAIVDTGTSLITGPSDKIKQLQNAIGAAPVDGEYAVECANLNV MPDVTFTINGVPYTLSPTAYTLLDFVDGMQFCSSGFQGLDIHPPAGPLWI LGDVFIRQFYSVFDRGNNRVGLAPAVPVDHHHHHH |
| 预测分子量 | 42 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTSE(Cathepsin E)重组蛋白的3篇代表性文献摘要信息：
---
1. **文献名称**：*"Expression and purification of recombinant human cathepsin E in Escherichia coli"*
**作者**：Yamamoto K, et al.
**摘要**：该研究描述了利用大肠杆菌表达系统高效表达人源CTSE重组蛋白的优化方法，并通过亲和层析技术实现纯化。实验验证了重组蛋白的酶活性，并探讨了其最适pH和抑制剂特性。
---
2. **文献名称**：*"Structural insights into the activation of cathepsin E by acidic conditions and substrate binding"*
**作者**：Tatnell PJ, et al.
**摘要**：通过X射线晶体学解析了重组CTSE蛋白在酸性条件下的三维结构，揭示了其自激活机制和底物结合位点的构象变化，为CTSE在肿瘤微环境中的功能提供了分子基础。
---
3. **文献名称**：*"Recombinant cathepsin E triggers endoplasmic reticulum stress-mediated apoptosis in cancer cells"*
**作者**：Chen X, et al.
**摘要**：研究利用昆虫细胞表达系统制备了功能性CTSE重组蛋白，发现其通过诱导内质网应激通路选择性促进癌细胞凋亡，提示其在癌症靶向治疗中的潜在应用价值。
---
注：以上文献信息为示例性质，实际文献需通过PubMed或Web of Science等数据库检索确认。若需具体文献链接或补充，可进一步说明研究方向(如表达系统、疾病机制等)。
**Background of Recombinant CTSE Protein**
Cathepsin E (CTSE), a member of the aspartic protease family, is an intracellular protease predominantly expressed in immune-related cells, such as antigen-presenting cells (e.g., macrophages, dendritic cells) and gastric epithelial cells. Unlike other cathepsins (e.g., Cathepsin D or B), CTSE is distinguished by its strict intracellular localization, limited tissue distribution, and unique enzymatic activity, functioning optimally in acidic environments (pH 3.0–5.0). It plays critical roles in antigen processing, immune regulation, and maintaining gastric mucosal homeostasis. Dysregulation of CTSE has been implicated in inflammatory diseases, autoimmune disorders, and cancer progression, highlighting its therapeutic and diagnostic potential.
Recombinant CTSE protein is engineered using genetic cloning techniques, often expressed in mammalian or insect cell systems to ensure proper post-translational modifications and enzymatic activity. The purified protein retains native structural and functional properties, enabling in vitro studies to dissect its biological mechanisms, screen inhibitors, or explore its role in disease pathways. Researchers leverage recombinant CTSE to investigate its interactions with immune receptors, such as major histocompatibility complex (MHC) molecules, and its involvement in degrading pathogenic antigens or regulating apoptosis.
The development of recombinant CTSE also supports biomedical applications, including drug discovery for autoimmune conditions or cancers where CTSE overexpression correlates with poor prognosis. Additionally, it serves as a tool for diagnostic assay development, aiding in biomarker detection. Continued research on recombinant CTSE aims to unravel its dual roles in health and disease, offering insights into targeted therapies and immune modulation strategies.
×
